Modified vitamin K-dependent polypeptides
The invention provides vitamin K-dependent polypeptides with enhanced membrane binding affinity. These polypeptides can be used to modulate clot formation in mammals. Methods of modulating clot formation in mammals are also described.
1. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a mutant Factor VII (FVII) or mutant Factor VIIa (FVIIa) polypeptide, wherein said mutant FVII or mutant FVIIa polypeptide comprises a modified γ-carboxyglutamic (GLA) domain that enhances membrane binding affinity of said mutant FVII or mutant FVIIa polypeptide relative to a wild type human Factor VII (hFVII) or wild type human Factor VIIa (hFVIIa) polypeptide, wherein said modified GLA domain comprises an amino acid sequence that differs form the amino acid sequence of the GLA domain of wild type hFVII or wild type hFVIIa polypeptide shown in SEQ ID NO: 3 in 1 to 5 amino acid substitutions, wherein the proline residue at amino acid position 10 of SEQ ID NO: 3 is substituted with a glutamine, aspartic acid or glutamic acid residue in the modified GLA domain.
2. The pharmaceutical composition of claim 1 , wherein said pharmaceutical composition further comprises soluble tissue factor.
3. The pharmaceutical composition of claim 1 , wherein the proline residue at position 10 of SEQ ID NO:3 is substituted with a glutamine residue in the modified GLA domain.
4. The pharmaceutical composition of claim 1 , wherein the arginine residue at position 28 of SEQ ID NO:3 is substituted with a different amino acid residue in the modified GLA domain.
5. The pharmaceutical composition of claim 4 , wherein the arginine residue at position 28 of SEQ ID NO:3 is substituted with a phenylalanine residue in the modified GLA domain.
6. The pharmaceutical composition of claim 5 , wherein the proline residue at position 10 of SEQ ID NO:3 is substituted with a glutamine residue in the modified GLA domain.
7. The pharmaceutical composition of claim 1 , wherein the lysine residue at position 32 of SEQ ID NO:3 is substituted with a different amino acid residue in the modified GLA domain.
8. The pharmaceutical composition of claim 7 , wherein the lysine residue at position 32 of SEQ ID NO:3 is substituted with a glutamic acid residue in the modified GLA domain.
9. The pharmaceutical composition of claim 7 , wherein the lysine residue at position 32 of SEQ ID NO:3 is substituted with an aspartic acid residue in the modified GLA domain.
10. The pharmaceutical composition of claim 8 , wherein the proline residue at position 10 of SEQ ID NO:3 is substituted with a glutamine residue in the modified GLA domain.
11. The pharmaceutical composition of claim 9 , wherein the proline residue at position 10 of SEQ ID NO:3 is substituted with a glutamine residue in the modified GLA domain.
12. The pharmaceutical composition of claim 1 , wherein the glycine residue at position 11 of SEQ ID NO:3 is substituted with a different amino acid residue in the modified GLA domain.
13. The pharmaceutical composition of claim 12 , wherein the proline residue at position 10 of SEQ ID NO:3 is substituted with a glutamine residue in the modified GLA domain.
14. The pharmaceutical composition of claim 1 , wherein the pharmaceutical composition comprises the pharmaceutically acceptable carrier and the mutant Factor VIIa polypeptide.
15. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a mutant FVII or mutant FVIIa polypeptide, wherein the mutant FVII or mutant FVIIa polypeptide comprises a modified GLA domain that enhances membrane binding affinity of the mutant FVII or mutant FVIIa polypeptide relative to a wild type hFVII or wild type hFVIIa polypeptide, wherein said modified GLA domain comprises an amino acid sequence that differs from the amino acid sequence of the GLA domain of wild type hFVII or wild type hFVIIa polypeptide shown in SEQ ID NO: 3 in two amino acid substitutions, wherein a glutamine residue is substituted for the proline residue at amino acid position 10 of SEQ ID NO: 3 and a glutamic acid residue is substituted for the lysine residue at position 32 of SEQ ID NO: 3 in the modified GLA domain.
16. The pharmaceutical composition of claim 15 , wherein the pharmaceutical composition comprises the pharmaceutically acceptable carrier and the mutant Factor VIIa polypeptide.